arrow
S

Sergio Giralt

Memorial Sloan Kettering Cancer Center
H指数:122
被引数:6.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sugar-rich foods exacerbate antibiotic-induced microbiome disruption

高糖食物加剧抗生素诱导的微生物组紊乱

Nature
IF48.5
2026-09-300
OAAI
Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

自体干细胞移植后微小残留病阴性及多发性骨髓瘤自体移植的生存结局

2026-09-220
OAAI
HLA-A ∗01:01 Allele Is Associated With Increased Risk of Transplant-Related Mortality After MHC Matched Unmodified Allogeneic Hematopoietic Stem Cell Transplantation

HLA-A*01:01等位基因与MHC匹配的未修饰同种异基因造血干细胞移植后移植相关死亡风险增加相关

2026-09-070
OAAI
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma

基于病灶水平的PET/CT分析以识别多发性骨髓瘤中BCMA CAR T细胞治疗后进展的预测因子

2026-08-190
OAAI
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

粒细胞集落刺激因子对双特异性抗体启动期间细胞因子释放综合征的影响:在复发/难治性多发性骨髓瘤中的作用

2026-08-070
OAAI
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma

在多发性骨髓瘤患者中,强效CD4+ CAR T细胞扩增与非ICANS神经毒性的发生相关(cilta-cel治疗)

2026-07-290
PRE
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma

BCMA和GPRC5D嵌合抗原受体(CAR)T细胞在晚期多发性骨髓瘤中的联合给药

Blood
IF23.1
2026-07-080
PRE
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

功能性高风险疾病与多发性骨髓瘤晚期CAR T细胞疗法后的不良预后相关

2026-04-120
OAAI
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations

TP53突变携带的髓系恶性肿瘤中,移植后干预和慢性移植物抗宿主病对生存的影响

2026-04-120
PRE
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

CXCL9作为一种新型预后标志物,用于识别患有噬血细胞性淋巴组织细胞增多症的成人高风险群体。

Blood
IF23.1
2026-02-263
PRE
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM

IMS-IMWG 2025年共识基因组分期可预测达雷木单抗为基础的四联方案对NDMM的疗效。

2026-02-190
OAAI
Time-of-Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

CAR T细胞输注的昼夜时间与弥漫性大B细胞淋巴瘤的结局

Blood
IF23.1
2025-12-260
OAAI
Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis

高危移植相关血栓性微血管病成人中终末补体阻滞的结局:一项比较分析

2025-11-280
PRE
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort

异基因造血细胞移植在未达完全缓解的急性髓系白血病中的应用:当代队列的结局与预后因素

2025-11-250
OAAI
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

大B细胞淋巴瘤中CAR T细胞疗法后的晚期血液学毒性:发生率、危险因素及临床影响

2025-11-180
PRE
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

双特异性抗体治疗复发/难治性多发性骨髓瘤期间巨细胞病毒再激活

2025-11-010
OAAI